Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble

May 31 2013

• By Alex Lash and Paul Bonanos

Related Content

Almost All Hopes Dashed For Pfizer/Medivation's Dimebon

Apr 11 2011

Roche Agrees To Acquire HCV Biotech Anadys For $230 Million

Oct 17 2011

Ironwood Pharmaceuticals: Independent for the Long Haul

Sep 01 2010

Biotech Angels Are Going Where VCs Fear To Tread

Feb 01 2011

Launching Linzess Into A Tough Primary Care Market

Dec 22 2012

Ironwood Adds A China Wrinkle To Regional Deal Strategy

Dec 19 2012

The Alnylam Turnaround: What Changed Investors’ Minds?

Sep 12 2012

Epizyme Builds A Cancer Company At Mach Speed

May 23 2012

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

May 21 2013

Related Companies

Pharmasset, Inc.

Gilead Sciences, Inc.

Epizyme, Inc.

Bristol Myers Squibb Company

Biogen, Inc.

Vertex Pharmaceuticals Incorporated

Amgen, Inc.

Onyx Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Clovis Oncology, Inc.

Alnylam Pharmaceuticals Inc.

Medivation, Inc.

Sarepta Therapeutics, Inc.

Acadia Pharmaceuticals Inc.

Iveric Bio, Inc.

OSI Systems, Inc.

eFFECTOR Therapeutics, Inc.

GSK plc

University of California San Francisco

Anadys Pharmaceuticals, Inc.

Roche Holding AG

Novartis AG

Karyopharm Therapeutics

Ironwood Pharmaceuticals, Inc.

Forest Laboratories, Inc.

Almirall SA

AstraZeneca PLC

Astellas Pharma, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window